Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam P Dicker

Showing results (61-70 of 286) with videos related to

Pageof 29
Sort By:
Practical Radiation Oncology|May 25, 2023
Practical Steps to Mitigate Cybersecurity Attacks on Radiation Oncology PracticesJames B Yu, Adam P Dicker, Nataniel H Lester-Coll, et al.
Expert Review of Anticancer Therapy|October 16, 2013
Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?Nicholas G Zaorsky, Laura A Doyle, Mark D Hurwitz, et al.
Journal of Neuro-Oncology|April 26, 2011
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinicPhyllis R Wachsberger, Richard Yaacov Lawrence, Yi Liu, et al.
Journal of the American College of Radiology : JACR|December 19, 2012
Predictors of radiation oncology resident research productivityJordan M Gutovich, Robert B Den, Maria Werner-Wasik, et al.
Expert Review of Medical Devices|December 26, 2014
Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected]Nicholas George Zaorsky, Mark D Hurwitz, Adam P Dicker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish modelBorbala Daroczi, Gabor Kari, Mary Frances McAleer, et al.
Frontiers in Oncology|February 6, 2013
Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiationPhyllis Rachelle Wachsberger, Richard Yaacov Lawrence, Yi Liu, et al.
Expert Review of Medical Devices|November 8, 2013
Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancerNicholas G Zaorsky, Robert B Den, Laura A Doyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastomaPhyllis R Wachsberger, Randy Burd, Nichol Marero, et al.
Journal of Oncology Practice|November 28, 2012
Pilot study of meaningful use of electronic health records in radiation oncologyXinglei Shen, Adam P Dicker, Laura Doyle, et al.
Pageof 29

Showing results (61-70 of 286) with videos related to

Sort By:
Pageof 29
Practical Radiation Oncology|May 25, 2023
Practical Steps to Mitigate Cybersecurity Attacks on Radiation Oncology PracticesJames B Yu, Adam P Dicker, Nataniel H Lester-Coll, et al.
Expert Review of Anticancer Therapy|October 16, 2013
Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?Nicholas G Zaorsky, Laura A Doyle, Mark D Hurwitz, et al.
Journal of Neuro-Oncology|April 26, 2011
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinicPhyllis R Wachsberger, Richard Yaacov Lawrence, Yi Liu, et al.
Journal of the American College of Radiology : JACR|December 19, 2012
Predictors of radiation oncology resident research productivityJordan M Gutovich, Robert B Den, Maria Werner-Wasik, et al.
Expert Review of Medical Devices|December 26, 2014
Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected]Nicholas George Zaorsky, Mark D Hurwitz, Adam P Dicker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish modelBorbala Daroczi, Gabor Kari, Mary Frances McAleer, et al.
Frontiers in Oncology|February 6, 2013
Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiationPhyllis Rachelle Wachsberger, Richard Yaacov Lawrence, Yi Liu, et al.
Expert Review of Medical Devices|November 8, 2013
Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancerNicholas G Zaorsky, Robert B Den, Laura A Doyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastomaPhyllis R Wachsberger, Randy Burd, Nichol Marero, et al.
Journal of Oncology Practice|November 28, 2012
Pilot study of meaningful use of electronic health records in radiation oncologyXinglei Shen, Adam P Dicker, Laura Doyle, et al.
Pageof 29